5th Tumor Models Boston July 2017 Brochure

July 18-20 2017, Boston, MA
Researched & Developed By:
Event Partners Including:
Uncover the Latest Preclinical & Clinical
Insights to Advance Your Oncology Pipeline
Tel: +1 212 537 5898 | Email: info@tumor-models.com Tumor Models
www.tumor-models.com
30+ Expert Speakers Including:
Barbara Joyce-Shaikh
Associate Principal Scientist, Immunoncology
Merck Research Laboratories
Hui Wang
Principal Scientist, In Vivo Pharmacology,
Oncology Research & Development
Pfizer
Andrew Rhim
CPRIT Scholar in Cancer Research, Associate
Director for Translational Research in Pancreatic
Cancer Research
MD Anderson Cancer Center
David Teachey
Associate Professor of Pediatrics,
Divisions of Hematology and Oncology
Children’s Hospital of Philadelphia, University
of Pennsylvania School of Medicine
• Optimize Model Selection & Characterization
• Advance Your Preclinical Predictions into the Clinic
• Discover Valuable Clinical Data to Drive Your
Preclinical & Translational Studies
This conference was
amazing! The collaborations
I created are priceless.
Thanks so much!
Past Attendee of the Tumor Models
Series, Roswell Park Cancer Institute
Book now to save up to $700

Tumor Models Boston
Tel: +1 212 537 5898 Email: info@tumor-models.com
www.tumor-models.com Tumor Models
11
33
22
44
55
Optimize your strategies for selection &
characterization of in vivo preclinical models
Key takeaways to implement: Top case studies to discover:
Discover how Merck are advancing the use of
humanized mice models in the development
of cancer immunotherapies
Explore preclinical model advancements in
ex vivo assays, 3D models & organoid in vitro
models
Learn from Kite Pharma on how to utilize
ex vivo assays for the development of T cell
therapies
Take clinical outcomes from targeted & IO
therapies to advance preclinical development
& translational decision making
Uncover how Novartis are advancing in vitro
3D models to bridge the gap with animal
models
Evaluate your preclinical predictions for the
development of combination therapies with
targeted & immunotherapies
Explore how University of Penn Medical
School are harnessing clinical outcomes of
CAR-T therapies to enhance translational
insights from preclinical studies
Advance the predictability of preclinical models
through clinical insights from CAR-T
& immune-checkpoint therapies
Unlock how Genentech are developing and
harnessing toxicology models for safety
assessments of IO therapies
This was a nice
meeting with a good sized
group of participants that
made it easy to choose
to both sit back and
soak it all in or to meet
one-on-one for in-depth
discussions
Past Attendee of Tumor Models Boston,
Agilux Laboratories
It was a well-
structured meeting, with a
good balance of speakers,
social interaction and
exhibitors. I felt I got a lot
accomplished within a
very short period of time.
Most helpful for someone
with a busy schedule
Past Attendee of Tumor Models Boston,
KK Womens and Childrens Hospitals
Hear what previous
attendees have to say:
The only forum dedicated to advancing preclinical oncology for
optimized translational & clinical success
With the oncology industry rapidly transitioning from traditional targeted therapies to
cancer immunotherapies, particularly in combination, the preclinical research now needs
to harness the clinical findings to advance preclinical outcomes of future therapies.
The 5th Annual Tumor Models Boston continues to showcase the latest advancements
in the application of preclinical models to enhance the translation of cancer therapies
from animal to patient. Learn how the industry have been selecting & characterizing in
vitro models, ex vivo assays, syngeneic, PDX, humanized mice models to optimize their
application in preclinical and translational decision making for targeted therapies, IO
therapies and combination therapies.
With the industry well aware of the models available, you will uncover the valuable
clinical lessons that are helping to transform preclinical research to safeguard future
therapies. Discover how you can utilize clinical insights to extract more value from
preclinical models and accelerate more safe and effective drug candidates into the clinic
with greater confidence.
This year’s Tumor Models Boston will address the preclinical & clinical developments
of the most promising targeted and IO therapies including check-point inhibitors, CAR-T
therapies and how these findings can be utilized to bridge the gap between animal and
patient studies.
Now is the time to harness clinical data to dictate preclinical model development,
biomarker discovery & validation and combination therapy advancement. Take vital
lessons from the clinic to progress future cancer treatments into the clinic more
effectively and faster.
Discover the preclinical strategies that are driving translational & clinical outcomes
Catch up with the latest preclinical & clinical data to fast
track your compounds into the clinic with confidence

Tumor Models Boston
Dedicated Speaker Faculty
Tom Brennan
Vice President, Pharmacology &
Bioanalytics
FivePrime Therapeutics
Edward Rosfjord
Senior Principal Scientist
Pfizer
Jayant Thatte
General Manager
Crown Bioscience
Parker Cassidy
Chief Commercial Officer
Mitra Biotech
Renuka Iyer
Section Chief GI Medical Oncology
Roswell Park Cancer Institute
Saad Kenderian
Assistant Professor of Medicine &
Oncology
Mayo Clinic
Rick Huntress
Director of Business Development,
Clinical & In Vivo Services
The Jackson Laboratory
Shruthi Naik,
Research Associate, Department
of Molecular Medicine
Mayo Clinic
JoshuaBreunig
AssistantProfessor,BoardofGovernors
RegenerativeMedicineInstitute,
DepartmentofBiomedicalSciences
Cedars-Sinai Medical Center
Brian Van Ness
Professor, Department of Genetics,
Cell Biology & Development, College
of Biological Sciences
University of Minnesota Cancer
Center
Frederick Roberts
Sales Manager
Fujifilm VisualSonics
Mohammad Rashidian
Postdoctoralfellow,CancerResearch
Institute,BostonChildrenHospital
Harvard Medical School
Andrew Rhim
CPRITScholarinCancerResearch,
AssociateDirectorforTranslational
ResearchinPancreaticCancerResearch
Michael Brehm
Associate Professor, The Robert and
Sandra Glass Term Chair in Diabetes
University of Massachusetts
Medical School
Christopher Murriel
Senior Scientist II
OncoMed Pharmaceuticals
Jason Fleming
Professor Department of Surgical
Oncology
Neal Goodwin,
VP, Corporate Research
Development
Champions Oncology
David Largaespada
American Cancer Society Research
Professor, Department of Pediatrics,
Masonic Cancer Center
University of Minnesota
Vinagolu Rajasekhar
Senior Research Scientist
Memorial Sloan Kettering Cancer
Center
Sidi Chen
Assistant Professor,
Genetics
Yale University
Shiva Kazerounian
Senior Scientist
Berg Pharma
Ran Li
Postdoctoral Scientist, Roger
Kamm’s Lab, Department
of Biological Engineering &
Mechanical Engineering
MIT
Barbara Joyce-Shaikh
Associate Principal Scientist,
Immunoncology
Merck Research Laboratories
Serena Silver
Senior Investigator, Group Leader,
Oncology
Novartis Institutes for Biomedical
Research
David Teachey
Associate Professor of Pediatrics,
Divisions of Hematology & Oncology
Children’sHospitalofPhiladelphia,
UniversityofPennsylvaniaSchoolof
Medicine
Hui Wang
Principal Scientist, In Vivo
Pharmacology, Oncology Research
& Development
Pfizer
Gregor Adams
Principal Scientist
Kite Pharma Inc
Robert Li
Toxicologist, Pharmacology
SubTeam Leader Safety
Assessment
Genentech
Moony Tseng
Research Scientist II, Cancer Cell
Line Factory Project Lead
Broad Institute
Maryland Franklin
Vice President, Scientific
Development
MI Bioresearch
Jenni Bernoulli
COO
Pharmatest Services
Mohit Sachdeva
Senior Scientist
Horizon Discovery
Alison Allan
AssociateProfessor,Departmentsof
Anatomy&CellBiology&Oncology
SchulichSchoolofMedicineandDentistry
Western University
Leigh Ellis
AssistantProfessorofPathology,DepartmentofOncologic
Pathology
Dana-Farber Cancer Institute

Tumor Models Boston
The following questions will be answered:
• What are the current limitations with PDX models when
studying the tumor microenvironment?
• What methodologies are being used to develop
humanized mice models from PDX models?
• How is the development of humanized mice from PDX
models overcoming these limitations?
• What technical challenges need overcoming to harness
these models for therapeutic development?
Characterization of PDX Models in the Context of Humanized Mice
Date: Tuesday July 18, 2017 | Time: 8.30-11.30
Dr. Vinagolu K. Rajasekhar, a Senior Research Scientist at the Memorial Sloan-Kettering Cancer Center, has been developing
humanized patient derived xenograft (PDX) models of metastatic cancers in the institutional collaboration with Dr. John Healey,
the Chief of Orthopedics Service. Dr. Rajasekhar has also purified cancer stem cells (CSCs) from human prostate cancer
PDXs, discovered a novel set of biomarkers for the tumor driving cells, and delineated a clinically relevant functional signaling
pathway in prostate cancer (www.Genomeweb.com). This study unveils a new direction to live bio-bank patient CSC-derived
xenograft (PDXCSC) models of human tumors, which form an excellent and replenishable resource for understanding patient
personalized signaling cross-talks between the CSCs and their specific microenvironment as well as for therapeutic testing
and co-clinical trials.
Workshop leader
Vinagolu Rajasekhar, Senior Research Scientist, Memorial Sloan Kettering Cancer Center
Workshop A
The following questions will be addressed:
• How is the industry using humanized mice models for
cell therapy preclinical studies?
• What are the limitations in the current models for
developing ex vivo therapies?
• What strategies are the industry developing to test
CAR-T therapies in preclinical models?
• What developments are required to advance in vivo
models for the preclinical testing of ex vivo therapies?
Characterizing Preclinical Models for Advancing Cell Therapies
Saad S. Kenderian, MD is a senior associate consultant in the Division of Hematology at the Mayo Clinic. He holds the
academic rank of Assistant Professor of Medicine and Oncology, Mayo Clinic College of Medicine. After completing a combined
fellowship in hematology and medical oncology, he joined the Division of Hematology at Mayo, received the Mayo Scholar award
and joined the Translational Research Program of the University of Pennsylvania as a Mayo Scholar, where he worked in T cell
immunotherapy for over two years.
Workshop leader
Saad Kenderian, Assistant Professor of Medicine & Oncology, Mayo Clinic
Workshop B
Pre-Conference Workshop Day
The topics selected for this meeting are excellent and I would like
to see those topics at future meetings
Past Attendee of the Tumor Models Series, Dicerna Pharmaceuticals

Tumor Models Boston
The conference was very
informative. I especially
enjoyed the pre-conference
workshops. I learned a great
deal about the pros and
cons of the models used for
immunotherapy
Past Attendee of Tumor
Models Series, Calvert
Laboratories
The following areas will be discussed:
• What are the current methodologies to develop
humanized mice models?
• What are the limitations of humanized mice models in
preclinical practice?
• Case studies on the use of humanized mice models for
IO preclinical studies
• What future developments are required to utilize
humanized mice routinely?
Optimizing Humanized Mice Models for the Advancement of Cancer
Immunotherapies
Dr. Brehm received his Ph.D. from the Department of Microbiology and Immunology at the Pennsylvania State University
College of Medicine. He is currently an Assistant Professor in the Program in Molecular Medicine at the University of
Massachusetts Medical School and a member of the UMass Diabetes Center of Excellence. Dr. Brehm’s research program is
focused on understanding how human effector T cells are regulated, and his laboratory is actively using “humanized” mice to
model human T cell responses.
Barbara Joyce-Shaikh completed her B.S in with Molecular Biology at San Jose State University. She has more than 20 years
of biotech industry experience specializing in translational systems of immune function and immunoncology. She is currently
a Project Leader in the Discovery Immunoncology group at Merck Research Laboratories. Her current research utilizes
humanized mouse systems and is focused on understanding how tumor stroma and immune cell interactions can be altered
with novel immunomodulatory agents in different cancers.
Workshop Co-Leader
Michael Brehm, Associate Professor, The Robert and Sandra Glass Term Chair in Diabetes,
University of Massachusetts Medical School
Workshop Co-Leader
Barbara Joyce-Shaikh, Associate Principal Scientist, Immunoncology, Merck Research
Laboratories
Workshop C

Tumor Models Boston
Conference Day One | Wednesday July 19, 2017
8.00 Registration & Coffee
9.00 Chair’s Opening Remarks
Taking Learnings from the Clinic to Advance Preclinical Models & Translational Decision Making
Jayant Thatte, General
Manager, Crown
Bioscience
9.10 Translational Utility of PDX Models in Humanized Mice
• Analysis of SCLC PDX models in a n=1 HuTrial
• Provide a potential solution for stem cell donor-to-donor variability seen in humanized mice
Jason Fleming,
Professor Department
of Surgical Oncology,
MD Anderson Cancer
Center
9.40 Improving Translational Decision Making to Influence Clinical Trial
Design & Determine Endpoints
• Bridging the model to human gap through effective and predictive biomarker strategy
• Improving characterization of preclinical models
• Ensuring more robust and rigorous translational research that ultimately help shorten
development timelines
Rick Huntress,
Director of Business
Development, Clinical
& In Vivo Services, The
Jackson Laboratory
10.10 Patient-Derived Tumor Xenografts in Humanized NSG-SGM3 Mice:
A New Immuno-Oncology Platform
• The addition of 3 human cytokines (GM-CSF, IL-3 & Kit Ligand) into the NSG mouse
provide for a more robust myeloid compartment after humanization
• Showcase data on the myeloid engraftment kinetics and also show checkpoint inhibitor
efficacy against several PDX tumors
10.40 Morning Refreshments & Speed Networking
Track A:
Advancing the Characterization of Preclinical Models
Track B:
Optimizing Model Development for Immunotherapies
In Vivo Model Advancements: Syngeneic Models
Enhancing the Use of Humanized Mice Models in
Preclinical Studies
11.40 Development and Application of GEMM and GEMM-
derived Syngeneic Models in Immuno-Oncology Drug
Discovery
• Addressing the preclinical needs of GEMM and GEMM-derived
syngeneic models for IO drug discovery
• How to improve characterization of above models to help
model selection
• Providing examples of utilization of GEMM and GEMM-derived
syngeneic models in IO drug discovery
Hui Wang, Principal Scientist, In Vivo Pharmacology, Oncology
Research Development, Pfizer
11.40 Addressing the Latest Advancements in the
Development of Routine Humanized Mice for
Immunotherapies
• Discussing the latest developments in humanized mice
modeling
• Presenting data from studies utilizing humanized mice for IO
therapeutic development
Michael Brehm, Associate Professor, The Robert and Sandra
Glass Term Chair in Diabetes, University of Massachusetts
Medical School
12.10 Identification of Novel Immune Regulators of Tumor
Growth Using High-Throughput Screening In Vivo
• We have generated a comprehensive library of substantially
all human extracellular proteins including secreted proteins
and the extracellular domains of membrane-bound proteins
in soluble form
• A portion of this library called the immunome contains 700
proteins with structural features characteristic of immune-
activators and checkpoints
• The immunome library was screened in four syngeneic mouse
tumor models in vivo using RIPPSSM (Rapid In vivo Protein
Production System)
• Several hits were identified and CD80-Fc was prioritized for
therapeutic development based on relative efficacy and tumor
immune cell profiles
Tom Brennan, Vice President, Pharmacology Bioanalytics,
FivePrime Therapeutics
12.10 Humanized Mouse Models for Drug Discovery Research
• Utilization of human cancer cell lines to model different
aspects of human cancers
• Discussing the relevance of humanized mouse cell subset
profiles and how they compared to ex vivo human tumors and
syngeneic models
• Leveraging humanized systems for clinical translation,
combination therapies, and biomarker development
Barbara Joyce-Shaikh, Associate Principal Scientist, Merck

Tumor Models Boston
In Vivo Model Advancements:
PDX Models
Harnessing Ex Vivo Assays for the Development
of Cell Therapies
14.10 The Use of PDX Models to Support Oncology Drug
Development
• Standard-of-care treatment from the perspective of response
rates in the clinic and response rates in PDX
• Evaluating response of PDX to standard-of-care treatment to
validate this hypothesis and to identify dosages and schedules
that can be used to identify sensitive and resistant PDX
models
Edward Rosfjord, Senior Principal Scientist, Pfizer
14.10 Developing Ex Vivo Preclinical Models to Enhance
Translation from In Vitro to In Vivo for Cell Therapies
• What models are being utilized to predict efficacy of engineered
T-cell therapies?
• Addressing the limitations in current models and how the
industry are optimizing preclinical strategies for CAR-T cell
therapies
Gregor Adams, Principal Scientist, Kite Pharma Inc
14.40 Highly Characterized Patient-Derived Xenograft
Collections for Preclinical Studies
• Use of highly characterized PDX models allow efficient
preclinical drug screening
• Ex vivo proliferation studies using PDX models mirrors in vivo
studies
Mohit Sachdeva, Senior Scientist, Horizon Discovery
14.40 Preclinical Modeling of Chimeric Antigen Receptor T Cell
Therapy and Combination Immunotherapy
• Discussing preclinical modeling in CAR-T cell therapy
• Addressing how preclinical modeling can be used for the
evaluation of CAR-T cell toxicities
• Presenting strategies for the development of combination
immunotherapy
Saad Kenderian, Assistant Professor of Medicine Oncology,
Mayo Clinic
15.10 Use of High Frequency Ultrasound Imaging to Quantify
Drug Responses in Patient Derived Xenografts of Renal
Cell Carcinoma
• The assessment patient-specific drug resistance to anti-
angiogenic agents using the promising application of
thepatient-derived xenograft model
• To quantify responses to anti-angiogenic therapy within a
clinically relevant time window, providing actionable data to
inform therapy selection
Frederick Roberts, Sales Manager, Fujifilm VisualSonics
This session will finish at 15.25
15.10 Exploring Tumor Microenvironment Using Immuno-PET
as a Predictive Tool
• The effectiveness of immunotherapies is a direct result of
changes they evoke in the tumor microenvironment
• Identifying reproducible patterns in responders and non-
responders is key to explaining the failure or success of a
therapy
• Using immunoPET to explore dynamics of immune infiltrates in
response to therapy
Mohammad Rashidian, Postdoctoral fellow, Cancer Research
Institute, Boston Children Hospital, Harvard Medical School
12.40 Preclinical Mouse Models of Cancer Via Transposon-
Mediated Mutagenesis or Gene Transfer
• The development of the Sleeping Beauty (SB) transposon
for forward genetic screens in mice: Immunoproficient,
autochthonous models of cancer with clinically relevant
genetic and biologic features
• SB screens for sarcoma and mammary cancer: Identification
of drivers of specific tumor biology
• Using transposon-mediated gene delivery and CRISPR/Cas9
to model cancer in living mice
• Porcine models of cancer
David Largaespada, American Cancer Society Research
Professor, Department of Pediatrics, Masonic Cancer Center,
University of Minnesota
12.40 Focal Radiation in Combination with Chemotherapy
Immunotherapy
• Uses of focal radiation in preclinical oncology models
• Combining focal radiation with chemotherapy in a human triple
negative breast cancer model
• Focal radiation in combination with immuno-therapy in a
syngeneic murine glioblastoma model
Maryland Franklin, Vice President, Scientific Development,
MI Bioresearch
This session will finish at 12.55
13.10 Networking Lunch
15.40 Afternoon Refreshments Poster Session
16.10 Tumor Models Interactive Roundtable Session
In this 1 hour session, you will have the opportunity to catch up on the latest advancements within the field and learn from
your fellow colleagues in this interactive format. The topics that will be discussed are the following:
Developing
predictive humanized
mice- What are the
current limitations?
What added benefits
can organoid cultures
bring to preclinical
studies?
Fundamental pre-
clinical experimental
design: Setting up for
clinical success
How can we use
preclinical models optimize
the predictability of novel
combination therapies?
1 2 3 4
17.10 Chair’s Closing Remarks
17.15 Drinks Reception Hosted By Crown Bioscience

Tumor Models Boston
Conference Day Two | Thursday July 20, 2017
8.00 Networking Coffee
9.00 Chair’s Opening Remarks
Clinical Findings Experimental Platforms to Identify Effective IO Combinations
Neal Goodwin, VP,
Corporate Research
Development,
Champions Oncology
9.10 Advanced PDX Tumor Biology Platforms for Drug Advancement
• Harnessing large collections of PDX models for more resolute efficacy predictions and the discovery
of new therapeutic targets, resistance mechanisms, and biomarker signatures of response
• How robust systems of myeloid engraftment, including hematopoietic stem cells for immune-
oncology modeling and AML engraftment for high throughput multi-patient in vivo screens,
have now provided expanded PDX screening with a wider scope of therapeutic agents
• Advancement of coupled-PDX trials, where clinical trials are combined with companion PDX
studies to help guide follow-on trial design
Andrew Rhim, CPRIT
Scholar in Cancer
Research, Associate
Director for
Translational Research
in Pancreatic Cancer
Research, MD Anderson
Cancer Center
9.40 Evaluating Preclinical Predictions for the Development of
Combinations with Targeted Therapies Immunotherapies
• Describing models used and key considerations for experimental design
• Model responses and predictability of combination efficacy
Parker Cassidy, Chief
Commercial Officer,
Mitra Biotech
10.10 A Novel Phenotypic Platform for Predicting Tumor Immune
Response
• Showcasing a novel platform to study and characterize immune cell interactions in response
to therapies
• How can this platform advance preclinical predictions for IO therapies?
10.40 Morning Refreshments
Track A:
Advancing Translational Progression of
Targeted Therapies
Track B:
Advancing Translational Progression of
Immunotherapies
11.10 Reverse Translation: Evaluating the Predictability
of Preclinical Models Through Correlation
Analysis of Clinical Data for Targeted Therapies
• Discussing early clinical data and analysis into the correlation
of preclinical predictions from models with clinical data
• Addressing how clinical insights are optimizing preclinical
studies for future therapies or combination therapies
Christopher Murriel, Senior Scientist II, OncoMed
Pharmaceuticals
11.10 Highlighting Clinical Outcomes of CAR-T Therapies to
Enhance Translational Insights from Preclinical Models
• Harnessing valuable clinical insights to advance preclinical
translation for future therapies
• How have clinical learnings advanced preclinical studies to
better present the patient population
David Teachey, Associate Professor of Pediatrics, Divisions of
Hematology Oncology, Children’s Hospital of Philadelphia,
University of Pennsylvania School of Medicine
11.40 Modeling Development of a Gene Expression Signatures
of Response Resistance to Proteasome Inhibitors
• Demonstrate the use of cell line models to develop a gene
expression signature that predicts response or resistance to
proteasome inhibitors in myeloma
• Demonstrate gene signatures can be validated in stratification
of clinical trial outcomes.
• Show how gene expression signatures of therapeutic
response can be applied in single cells to identify tumor
heterogeneity in patients
• Show how computational approaches to identify predictive
signatures can be used using national data bases
Brian Van Ness, Professor, Department of Genetics, Cell
Biology Development, College of Biological Sciences,
University of Minnesota Cancer Center
11.40 BPM 31510, A Clinical Stage Candidate, Demonstrates
Potent Anti-Tumor Effect by Modulating Metabolism of
Immune Cells
• By improving the metabolic activity of immune-cells we can
improve the Immunotherapies.
• BPM31510 is a metabolic modulator
• BPM31510 demonstrates potent anti-tumor efficacy in
syngenic models
• BPM31510 modulates the level of tumor infiltrating cells in a
dose-dependent manner
Shiva Kazerounian, Senior Scientist, Berg Pharma

Tumor Models Boston
Addressing Preclinical Model Advancements:
Optimizing In Vitro Models
Clinical Learnings from Immunotherapies to Drive
Preclinical Predictions
13.40 Advances in In Vitro Model Development for
Oncology Drug Discovery
• Utilizing 3D models to understand the tumor
microenvironment and interactions with immune cells
• Addressing preclinical strategies to enhance the translation
between in vitro and in vivo preclinical studies
Serena Silver, Senior Investigator, Group Leader, Oncology,
Novartis Institutes for Biomedical Research
13.40 Harnessing Humanized Mice to Improve Preclinical
Predictions for Immuno Therapy and Nano Technology
Approaches to Treat Cancers
• Acknowledging and understanding the limitations of
humanized mouse models
• What does the perfect humanized model look like for ex vivo
applications?
Vinagolu Rajasekhar, Senior Research Scientist, Memorial
Sloan Kettering Cancer Center
14.10 Accelerating Prediction of Tumor Vulnerabilities Using
Next-Generation Cancer Models
• It is now possible to generate cell models at scale for many tumor
types; in-line genomics is required to iteratively improve methods
• Understanding the cancer cell model genomic stability across
passages is critical for profiling the small molecular and
genetic screens
• We aim to expand the knowledge of cancer dependency map
by adding the next generation cancer models
Moony Tseng, Research Scientist II, Cancer Cell Line Factory
Project Lead, Broad Institute
14.10 Influence of Microenvironment in Primary Bone
Tumor Breast Cancer Models
• Hormonal influence in orthotopic breast cancer tumor model
• Bone microenvironment and breast cancer tumor growth
• Immuno-oncology: tumor, bone and immune system in
humanized mice
Jenni Bernoulli, COO, Pharmatest Services
14.25 ModelingTumorMicroenvironmentUsingMicrofluidicSystems
• Utilizing microfluidic platforms to study cancer cell-immune
cell Interaction
• In vitro system to study the mechanobiology of immune cell in
the tumor microenvironment
• Developing microfluidic platforms for testing immunotherapy
Ran Li, Postdoctoral Scientist, Roger Kamm’s Lab, Department
of Biological Engineering Mechanical Engineering, MIT
14.40 Biological Advances to Help Navigate the Nonclinical
Safety Assessment Strategy in Cancer Immunotherapy
• Highlighting the unique challenges in preclinical safety
assessment for the development of cancer immunotherapeutics
which may not be optimally characterized using conventional
toxicology models or strategy
• Discussing the opportunities of modifying the conventional
toxicology models or developing novel approaches to support
clinically relevant hazard identification and risk assessment
Robert Li, Toxicologist, Pharmacology SubTeam Leader Safety
Assessment, Genentech
14.55 Circulating Tumor Cell (CTC) Analysis in Preclinical Models
of Cancer Metastasis
• Although a number of quantitative tools have been previously
developed to study in vivo metastasis, the detection and
quantification of rare metastatic events has remained challenging
• To discuss the use of circulating tumor cell (CTC) analysis as an
effective means of tracking and characterizing metastatic disease
progression in preclinical mouse models of breast and prostate
cancer.
• In particular, the use of clinically-relevant CTC technologies such
as the Parsortix platform (ANGLE plc) to enhance the translation
of cancer biology and new cancer therapies from animal to patient
Alison Allan, Associate Professor, Departments of Anatomy
Cell Biology Oncology Schulich School of Medicine and
Dentistry, Western University- In collaboration with Angle
12.10 Addressing the Woodchuck Model for Hepatitis B
Related HCC
• Using the woodchuck model in the preclinical development of
therapies for Hepatitis B related HCC
• Discussing the high translatability of the preclinical insights
gained from the woodchuck model into the clinic
Renuka Iyer, Section Chief GI Medical Oncology,
Roswell Park Cancer Institute
12.10 Comparative Oncology to Inform Clinical Translation of
Immunotherapies
• Overview and attributes of the Comparative Oncology approach
• Utility of Comparative Oncology to facilitate clinical translation
of Oncolytic virus and other immunotherapies
• Currently available tools and development of new tools in
development to facilitate immunotherapy development (e.g.
biomarkers, imaging, genomics)
Shruthi Naik, Research Associate, Department of Molecular
Medicine, Mayo Clinic
12.40 Networking lunch

Tumor Models Boston
15.10 Afternoon Refreshments
Next Generation Model Development: Harnessing CRISPR Precision Gene Editing
Sidi Chen, Assistant
Professor, Genetics,
Yale University
15.40 CRISPR Genome Editing Mouse Models of Cancer
• Harnessing CRISPR for the precise development of physiologically relevant preclinical in vivo
models for target discovery
• Developing knock out models that are personalized to individual tumor types
Joshua Breunig,
Assistant Professor,
Board of Governors
Regenerative Medicine
Institute, Department
of Biomedical
Sciences,
Cedars-Sinai Medical
Center
16.10 Combining CRISPR/Cas9 Gene Targeting Single-Copy Somatic
Transgenesis for Preclinical Brain Tumor Research
• Overview of novel genetic methodologies for rapid, autochthonous tumor modeling
• Using patient mutations in mouse models to accurately model clinical tumor subtypes in a
“personalized” manner
• Examples of preclinical studies investigating strategies to impede tumor growth and
development by immunotherapy, metabolic targeting, and therapeutic mimicry
• Employing CRISPR/Cas9 to enable rapid genetic manipulation of patient tumor cells for
investigating the mechanisms of tumorigenesis and subsequent recurrence
Leigh Ellis, Assistant
Professor of Pathology,
Department of
Oncologic Pathology,
Dana-Farber Cancer
Institute
16.40 Utilizing 3D Organoid Modeling and Gene Editing for Accelerated
Discovery in Prostate Cancer
• Generate and validate 3D organoid models of prostate cancer to predict in vivo therapeutic
response
• Employing gene editing technology to discover drivers of aggressive prostate cancer
• Harnessing gene editing to discover drivers of drug resistance in prostate cancer
17.10 Chair’s Closing Remarks
17.15 Close of the 5th Annual Tumor Models Boston 2017
Part of the Tumor Models Series

Tumor Models Boston
Horizon Discovery
Horizon Discovery combines long scientific heritage in
translational research with GENESIS™, a precision gene
editing platform incorporating rAAV, CRISPR and ZFN technologies. Horizon
supplies genetically-defined cell lines, gene-editing tools and services, custom
cell line generation, molecular reference standards, and contract research
services to approaching 1,000 academic, clinical and biopharmaceutical
organizations.
www.horizondiscovery.com
Programme Partner
Crown Bioscience
Crown Bioscience provides Translational Platforms focused on fast-tracking candidates to identify biomarkers and patient
responders based on the pharmacological response of human surrogate models. Power your Drug Discovery using the world’s
largest commercial collection of well-characterised PDX in passage (HuPrime) plus a curated, searchable database of patient,
genotypic and phenotypic data as well as pharmacological response (HuBase). Identify potential biomarkers (HuSignature™)
based on pharmacological response or use your biomarker signature to identify models available for screening to confirm
patient responder and non-responder populations (HuTrials™). Fast forward your drug discovery programs today.
Partners, Sponsors Exhibitors
Lead Partner
Champions Oncology
Champions Oncology was founded by renowned
specialists in the field of cancer diagnosis, treatment,
and research. The Champions Oncology team is comprised of seasoned
oncology professionals passionately dedicated to working to accelerate
oncology drug development, improve treatment outcomes and extend lives.
Our core platform, the Champions TumorGraft™ offers an enhanced xenograft
mouse avatar model for growing and testing human tumours. Champions
Personalized TumorGrafts™ empower patients and physicians using an in vivo
xenograft mouse avatar based diagnostic model that has shown to be predictive
of a patients’ clinical response to cancer treatments and anticancer therapies.
www.championsoncology.com
Expertise Partner
Additional Event Partners
The Jackson Laboratory
The Jackson Laboratory is an independent,
nonprofit biomedical research institution and a
National Cancer Institute-designated Cancer Center. Founded in 1929, the
Laboratory applies its eight decades of expertise in genetics to increase
understanding of human disease, advancing treatments and cures for
cancer, neurological and immune disorders, diabetes, aging and heart
disease. It models and interprets genomic complexity, integrates basic
research with clinical application, educates current and future scientists,
and empowers the global biomedical community by providing critical data,
tools and services.
www.jax.org
Expertise Partner
Mitra Biotech
Mitra Biotech is a global leader
in advancing personalized cancer
treatment and empowering drug development discovery.Our unique
CANscript™ platform delivers powerful, individualized treatment response
predictions —with exceptionally high correlation to clinical outcomes — to
inform patient-specific cancer treatment selection and enhance drug
discovery.
www.mitrabiotech.com
Expertise Partner
Become a Commercial Partner at Tumor Models Boston:
Contact
Diane McKenna
Commercial Director, Tumor Models
Tel: +1 212 537 5898
Email: info@tumor-models.com
www.crownbio.com
Envigo provides essential research services, models
and products for biopharmaceutical, crop protection,
and chemical companies as well as universities,
governments, and other research organizations. Our business is founded
on a dedication to customer service and the expertise and experience of our
3,800 people. With over 50 locations worldwide we are committed to helping
customers realize the full potential of their research and products as we work
together to build a healthier and safer world.
Programme Partner

Tumor Models Boston
Academics Register Pay before Friday May 26, 2017 Standard
Conference + 3 workshops $1796 (Save $600) $2096 (Save $300)
Conference + 1 workshop $1298 (Save $500) $1698 (Save $100)
Conference Only $1199 (Save $300) $1499
Workshop Only $299
Pricing Venue
Register
www.tumor-models.com/
register
Tel: +1 212 537 5898
Email: register@hansonwade.com
Mail:
Hanson Wade
4th Floor, 52 Grosvenor Gardens,
London, SW1W 0AU
• 10% discount – 3 delegates
• 15% discount – 4 delegates
• 20% discount – 5 or more delegates
Please note that discounts are only
valid when three or more delegates
from one company book and pay at
the same time and that discounts are
not applicable to academic pricing.
Group discounts cannot be used in
conjunction with other discounts.
Team Discounts*
Top 3 Benefits of Attending
1
2
3
Optimize Your Preclinical Studies
Advance Model Selection
Characterization
Discover Translational Insights
from the Clinic
Venue
The Colonnade Hotel
120 Huntington Avenue,
MA, 02116, USA
www.colonnadehotel.com
Full payment is due on registration. Cancellation and Substitution Policy:
Cancellations must be received in writing. If the cancellation is received more
than 14 days before the conference attendees will receive a full credit to a
future conference. Cancellations received 14 days or less (including the four-
teenth day) prior to the conference will be liable for the full fee. A substitution
from the same organization can be made at any time.
Changes to Conference Agenda: Hanson Wade reserves the right to
postpone or cancel an event, to change the location or alter the advertised
speakers. Hanson Wade is not responsible for any loss or damage or costs
incurred as a result of substitution, alteration, postponement or cancellation
of an event for any reason and including causes beyond its control including
without limitation, acts of God, natural disasters, sabotage, accident, trade or
industrial disputes, terrorism or hostilities.
Data Protection: The personal information shown and/or provided by you will
be held in a database. It may be used to keep you up to date with developments
in your industry. Sometimes your details may be obtained or made available to
third parties for marketing purposes. If you do not wish your details to be used
for this purpose, please write to: Database Manager, Hanson Wade, Suite A, 6
Honduras Street, London EC1Y 0TH
TERMS CONDITIONS
Code:7134
Excellent Tumor Models
meeting that was very well
attended. Great program,
speakers and panelists,
which made for productive
discussions, networking and
exchange of ideas
Past Attendee of the Tumor Models Series,
MedImmune
Drug Developers
(Pharma Biotech)
Register Pay before Friday May 26, 2017 Standard
Workshop Only $399
Solution, Service
Product Providers
Register Pay before Friday May 26, 2017 Standard
Workshop Only $499

5th Tumor Models Boston July 2017 Brochure

Recommended

Recommended

More Related Content

What's hot

What's hot (20)

Similar to 5th Tumor Models Boston July 2017 Brochure

Similar to 5th Tumor Models Boston July 2017 Brochure (20)

More from Diane McKenna

More from Diane McKenna (12)

Recently uploaded

Recently uploaded (20)

5th Tumor Models Boston July 2017 Brochure